HOME >> BIOLOGY >> NEWS
Study on chromosome ends may aid cancer research

PRINCETON, N.J. -- A Princeton scientist has discovered a mechanism that cells use to control the length of their chromosome ends, a process that is thought to go awry in cancer.

The finding, reported in the August 4 issue of Science by Professor of Molecular Biology Virginia Zakian and colleagues, may provide cancer researchers with clues for designing treatments.

Zakian found a naturally occurring protein that inhibits the activity of another protein, called telomerase, which replicates and lengthens the very ends of chromosomes. The protein, called Pif1p, acts directly on the chromosome ends, called telomeres, to keep the lengthening process in check, Zakian's research group reported.

Researchers have been studying telomerase with great intensity for the past 15 years because it appears to play a central role in the way cells age or become cancerous. Studies have shown that telomerase is present in 90 percent of cancer types, but is absent from most healthy cells. Cancer researchers have thus looked for ways to interfere with telomerase. Zakian's research suggests that mimicking or enhancing the action of Pif1p may be a good way to do so.

Telomerase builds structures called telomeres at the ends of chromosomes, like plastic caps at the ends of shoelaces. In normal conditions, telomeres shorten each time a cell divides, eventually exposing the genetic material and causing the cell to die. In cancer cells, however, telomerase keeps rebuilding the telomere caps, preventing the cell from undergoing its normal aging process.

In 1994, Zakian and collaborator Vincent Schulz reported that Pif1p keeps telomeres from lengthening. It remained unclear, however, how Pif1p accomplished that feat. There are many natural substances that could inhibit telomere lengthening in indirect ways, Zakian said. The new paper shows that Pif1p acts on the telomerase pathway itself and interacts directly with telomeric DNA, a potentially attractive feature for drug de
'"/>

Contact: Steven Schultz
sschultz@princeton.edu
609-258-5729
Princeton University
3-Aug-2000


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study chromosome ends may aid cancer research

(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
Cached News: